See what CanVECTOR members are publishing to advance the field of venous thromboembolism
Publications since 2016 that are linked to venous thromboembolism and/or anticoagulant therapy

Publications for Michael Boffa

Updated daily

Back to Member List

#	PubMedId	Deleted	Publication
	41177455	0	Clark JR, Sutherland FS, Assini JM, et al. Lipoprotein(a) prolongs ex vivo plasma clot lysis times through effects on clot formation rate and fibrin structure. J Thromb Haemost. 2025 Oct 31:S1538-7836(25)00674-9. doi: 10.1016/j.jtha.2025.10.009.
	40772299	0	Koschinsky ML, Boffa MB. Lp(a) as a Risk Factor for Peripheral Artery Disease: Context Is Everything. Arterioscler Thromb Vasc Biol. 2025 Aug 7. doi: 10.1161/ATVBAHA.125.322137.
	40748007	0	Assini JM, Boffa MB, Koschinsky ML. The complex pro-atherosclerotic role of lipoprotein(a): a multiplicity of cellular targets. Curr Opin Lipidol. 2025 Aug 4. doi: 10.1097/MOL.0000000000001000.
	40334781	0	Rosenson RS, Tate AM, Grushko OG, et al. Lipoprotein (a) integrates monocyte-mediated thrombosis and inflammation in atherosclerotic cardiovascular disease. J Lipid Res. 2025 May 5:100820. doi: 10.1016/j.jlr.2025.100820.
	39306544	0	Bruwer D, de Lange-Loots Z, Koschinsky ML, et al. Fibrinogen and plasma clot properties are associated with apolipoprotein B and apolipoprotein B-containing lipoproteins in Africans. J Clin Lipidol. 2024 Aug 12:S1933-2874(24)00231-9. doi: 10.1016/j.jacl.2024.08.004.
	39302109	0	Boffa MB, Koschinsky ML. Lipoprotein(a) and cardiovascular disease. Biochem J. 2024 Oct 2;481(19):1277-1296. doi: 10.1042/BCJ20240037.
	37310666	0	Garabon JJW, Boffa MB. Profibrinolytic effects of rivaroxaban are mediated by thrombin-activatable fibrinolysis inhibitor and are attenuated by a naturally occurring stabilizing mutation in enzyme. J Thromb Thrombolysis. 2023 Aug;56(2):283-290. doi: 10.1007/s11239-023-02837-3. Epub 2023 Jun 13.
	36759279	0	Zheng Z, Mukhametova L, Boffa MB, et al. Assays to quantify fibrinolysis: strengths and limitations. Communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on fibrinolysis. J Thromb Haemost. 2023 Jan 14:S1538-7836(23)00036-3. doi: 10.1016/j.jtha.2023.01.008.
	36299837	0	Farrugia S, Cachia M, Degaetano J, et al. Palmar Digital Vein Thrombosis: A Case Report and Review of 36 Cases. Eur J Case Rep Intern Med. 2022 Sep 21;9(9):003552. doi: 10.12890/2022_003552. eCollection 2022.
	35606079	0	Boffa MB. Beyond fibrinolysis: The confounding role of Lp(a) in thrombosis. Atherosclerosis. 2022 May;349:72-81. doi: 10.1016/j.atherosclerosis.2022.04.009.
	35520371	0	Farrugia S, Micallef D, Pisani D, et al. Retiform Purpura of the Lower Limbs Associated with Levamisole-Adulterated Cocaine. Eur J Case Rep Intern Med. 2022 Apr 28;9(4):003353. doi: 10.12890/2022_003353. eCollection 2022.
	31551368	0	Boffa MB, Marar TT, Yeang C, et al. Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis. J Lipid Res. 2019 Dec;60(12):2082-2089. doi: 10.1194/jlr.P094763. Epub 2019 Sep 24.
	31088940	0	Christiansen SD, Liu J, Boffa MB, et al. Simultaneous R2(*) and quantitative susceptibility mapping measurement enables differentiation of thrombus hematocrit and age: an in vitro study at 3 T. J Neurointerv Surg. 2019 Nov;11(11):1155-1161. doi: 10.1136/neurintsurg-2019-014802. Epub 2019 May 14.
	30316749	0	Boffa MB, Stranges S, Klar N, et al. Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal. J Clin Lipidol. 2018 Nov - Dec;12(6):1358-1366. doi: 10.1016/j.jacl.2018.08.012. Epub 2018 Sep 11.
	29528858	0	Boffa MB, Koschinsky ML. The journey towards understanding lipoprotein(a) and cardiovascular disease risk: are we there yet? Curr Opin Lipidol. 2018 Jun;29(3):259-267. doi: 10.1097/MOL.0000000000000499.
	26647358	0	Boffa MB, Koschinsky ML. Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? J Lipid Res. 2016 May;57(5):745-57. doi: 10.1194/jlr.R060582. Epub 2015 Dec 8.